PFG Investments LLC Makes New $32,000 Investment in Xilio Therapeutics, Inc. (NASDAQ:XLO)

PFG Investments LLC bought a new stake in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the first quarter, HoldingsChannel reports. The fund bought 30,000 shares of the company’s stock, valued at approximately $32,000.

Xilio Therapeutics Price Performance

Shares of Xilio Therapeutics stock traded up $0.13 on Friday, hitting $1.18. The company had a trading volume of 265,432 shares, compared to its average volume of 400,336. Xilio Therapeutics, Inc. has a twelve month low of $0.49 and a twelve month high of $3.25. The stock has a 50-day moving average of $0.97 and a 200-day moving average of $1.00. The firm has a market capitalization of $43.55 million, a P/E ratio of -0.42 and a beta of -0.13.

Xilio Therapeutics (NASDAQ:XLO) last announced its earnings results on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. Equities analysts predict that Xilio Therapeutics, Inc. will post -1.53 EPS for the current year.

Insider Buying and Selling

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. acquired 485,250 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were bought at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the acquisition, the insider now directly owns 7,345,473 shares of the company’s stock, valued at $5,582,559.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is owned by corporate insiders.

Xilio Therapeutics Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.